Back to curriculum
Domain

Heart Failure

Modules

The Four Pillars of GDMT in HFrEF

ARNI, beta-blocker, MRA, SGLT2i — start all four, titrate simultaneously.

Neurohormonal Activation in HFrEF

↓ Cardiac outputRAAS activationSympathetic activationARNI / ACEi/ARB blocksMRA blocks aldosteroneBeta-blocker blocks NE/HRSGLT2i — natriuresis,independent pathwayEach GDMT pillar interrupts a distinct point in the cascade — additive, not redundant, benefit

In HFrEF, reduced cardiac output triggers compensatory activation of the renin-angiotensin-aldosterone system and the sympathetic nervous system, which initially preserve perfusion but drive pathologic remodeling, fibrosis, and myocyte loss over time. Angiotensin II and aldosterone promote vasoconstriction, sodium retention, and hypertrophy, while chronic sympathetic activation increases myocardial oxygen demand and predisposes to arrhythmia. The natriuretic peptide system counter-regulates these effects but is relatively overwhelmed as disease progresses. GDMT pillars each interrupt a distinct point in this cascade, which is why combining them produces additive rather than redundant benefit.

ARNI (or ACEi/ARB)

1ARNI(or ACEi/ARB)Sacubitril-valsartan preferred2Beta-blockerCarvedilol,succinate,or bisoprolol3MRASpironolactoneor eplerenoneWatch K+, eGFR4SGLT2iDapagliflozin orempagliflozinAny diabetes statusStart all four at low dose in parallel — uptitrate each as tolerated, not in sequenceDiagram of the renin-angiotensin-aldosterone (RAAS) pathway (Wikimedia Commons, CC BY-SA 4.0)Sacubitril/valsartan preferred over ACEi/ARB when tolerated. Start 24/26 or 49/51 mg BID; target 97/103 mg BID. 36h ACEi washout required.

Evidence-Based Beta-Blocker

Carvedilol, metoprolol succinate, or bisoprolol. Start low, double every 2 weeks. Do not withhold in decompensation unless cardiogenic shock.

MRA

Spironolactone or eplerenone. Contraindicated at eGFR <30 or K >5.0. Recheck K and Cr within 1 week.

SGLT2 Inhibitor

Dapagliflozin or empagliflozin, regardless of diabetes status. Benefits within weeks.

Additional Therapies

IV iron (ferric carboxymaltose) if iron deficient. Hydralazine + ISDN in Black patients on GDMT. Vericiguat in worsening HF despite optimal GDMT.

Sequencing and Titration in Practice

Rather than titrating one drug class to target dose before starting the next, contemporary practice favors rapid initiation of all four pillars — ARNI or ACE-I/ARB, beta-blocker, MRA, and SGLT2 inhibitor — at low doses, then uptitrating each in parallel as tolerated. SGLT2 inhibitors in particular require no titration and can be started at the target dose from day one.
Clinical pearls
·
Sequence is less important than getting to all four. Do not wait for maximal titration of one before starting the next.
·
Ivabradine reduces HF hospitalization in HFrEF with sinus rhythm and HR ≥70 despite maximal beta-blocker.
·
ARNI initiation requires a 36-hour washout after stopping an ACE inhibitor to reduce angioedema risk (no washout needed when switching from an ARB).
·
SGLT2 inhibitor benefit in HFrEF is independent of diabetes status and can appear within weeks of initiation.
·
Beta-blockers should be started at low dose and up-titrated only in euvolemic, hemodynamically stable patients — avoid initiating during active decompensation.
Related guidelines